{"id":"NCT00932321","sponsor":"Warner Chilcott","briefTitle":"Study of Safety and Efficacy of an Oral Contraceptive","officialTitle":"Open Label, Randomized, Comparator-Controlled Study of the Contraceptive Efficacy of Norethindrone Acetate (NA) and Ethinyl Estradiol (EE)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2004-01","primaryCompletion":"2004-11","completion":"2004-11","firstPosted":"2009-07-03","resultsPosted":"2011-03-22","lastUpdate":"2013-04-22"},"enrollment":938,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Prevention of Pregnancy"],"interventions":[{"type":"DRUG","name":"Norethindrone Acetate/Ethinyl Estradiol 24 Days","otherNames":[]},{"type":"DRUG","name":"Norethindrone Acetate /Ethinyl Estradiol 21 Days","otherNames":["21 Day NA/EE"]}],"arms":[{"label":"24 Day NA/EE","type":"EXPERIMENTAL"},{"label":"21 Day NA/EE","type":"ACTIVE_COMPARATOR"}],"summary":"This is a comparative study. The primary objective of the study is to assess the efficacy of a low dose oral contraceptive in the prevention of pregnancy. The secondary objectives are to assess the incidence of intracyclic bleeding of norethindrone acetate/ethinyl estradiol (NETA/EE) administered for 24 days and NETA/EE administered for 21 days; and to assess the safety and tolerability of the product.","primaryOutcome":{"measure":"Pregnancy Rate (Expressed as Pearl Index) for Women 18 to 45 Years Old, MITT Population","timeFrame":"5.6 months (6 - 28 day cycles)","effectByArm":[{"arm":"24 Day NA/EE","deltaMin":1.823,"sd":null},{"arm":"21 Day NA/EE","deltaMin":2.978,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":true,"inclusionCount":4,"exclusionCount":3},"locations":{"siteCount":34,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":743},"commonTop":["Headache","Vaginal Candidiasis","Upper Respiratory Tract Infection","Nausea","Dysmenorrhea"]}}